Health Condition 1: H108- Other conjunctivitis Health Condition 2: null- vernal keratoconjunctivitis
Conditions
Interventions
Control Intervention1: nil: it is an observational study in which patients of vernal keratoconjunctivitis treated with dual acting antihistamines and mast cell stabilisers will be analysed for clinica
Sponsors
All India Institute of Medical SciencesRishikesh
Eligibility
Inclusion criteria
Inclusion criteria: patients with a clinical diagnosis of vernal keratoconjunctivitis. patients of either gender > 5 years. patients should be willing to consent for all required study visits and follow instructions from study investigators.
Exclusion criteria
Exclusion criteria: Patients who are in active stage of any other ocular inflammatory disease besides VKC Presence of glaucoma, uveitis. Patients on any oral or topical steroids. Pregnant or lactating women. Presence of systemic diseases other than co existing allergic rhinitis, asthma and atopic dermatitis Any documented H/O hypersensitivity to the said drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resolution of signs and symptoms in patients of vernal keratoconjunctivitis treated with dual acting antihistamines and mast cell stabilisers.Timepoint: 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Resolution of signs and symptoms in patients of vernal keratoconjunctivitis treated with dual acting antihistamines and mast cell stabilisers.Timepoint: 2 Weeks | — |
Countries
India
Contacts
Public ContactDr Preeti Yadav
Aiims Rishikesh
Outcome results
None listed